CN117321079A - 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 - Google Patents

包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 Download PDF

Info

Publication number
CN117321079A
CN117321079A CN202280009724.5A CN202280009724A CN117321079A CN 117321079 A CN117321079 A CN 117321079A CN 202280009724 A CN202280009724 A CN 202280009724A CN 117321079 A CN117321079 A CN 117321079A
Authority
CN
China
Prior art keywords
ser
val
pro
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280009724.5A
Other languages
English (en)
Chinese (zh)
Inventor
权炳世
李汉娜
朴振成
韩胜熙
孙贤泰
金孙宇
朴赫俊
柳恩惠
朴成敏
吴妍智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eutilex Co Ltd
Original Assignee
Eutilex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd
Publication of CN117321079A publication Critical patent/CN117321079A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280009724.5A 2021-01-11 2022-01-11 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 Pending CN117321079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135812P 2021-01-11 2021-01-11
US63/135,812 2021-01-11
PCT/IB2022/000009 WO2022149050A2 (en) 2021-01-11 2022-01-11 Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof

Publications (1)

Publication Number Publication Date
CN117321079A true CN117321079A (zh) 2023-12-29

Family

ID=82357225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280009724.5A Pending CN117321079A (zh) 2021-01-11 2022-01-11 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途

Country Status (6)

Country Link
US (1) US12331116B2 (enExample)
EP (1) EP4274852A4 (enExample)
JP (1) JP2024502371A (enExample)
KR (2) KR102618718B1 (enExample)
CN (1) CN117321079A (enExample)
WO (1) WO2022149050A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
USD1094401S1 (en) * 2023-02-20 2025-09-23 Sony Interactive Entertainment Inc. Display screen or portion thereof with transitional graphical user interface

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127467A1 (en) * 2015-07-30 2019-05-02 Macrogenics, Inc. PD-1-Binding Molecules and Methods of Use Thereof
CN110087682A (zh) * 2016-12-19 2019-08-02 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
CN110392696A (zh) * 2017-01-06 2019-10-29 优特力克斯有限公司 抗-人4-1bb抗体及其应用
CN110627906A (zh) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 抗pd-l1/4-1bb双特异性抗体及其用途
CN110669137A (zh) * 2019-10-24 2020-01-10 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
US20200165349A1 (en) * 2017-08-04 2020-05-28 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102178323B1 (ko) * 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
KR102259232B1 (ko) * 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
CA3047070A1 (en) * 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
US11718679B2 (en) * 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
KR20240017090A (ko) * 2018-03-23 2024-02-06 일라이 릴리 앤드 캄파니 항-pd-1 항체와의 조합을 위한 항-cd137 항체
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
MX2021002292A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
KR20210058902A (ko) * 2018-09-14 2021-05-24 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 sPD-1 변이체-FC 융합 단백질
WO2020068500A1 (en) * 2018-09-26 2020-04-02 Albert Einstein College Of Medicine Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
US20220220215A1 (en) * 2019-05-15 2022-07-14 Crescendo Biologics Limited Binding molecules
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127467A1 (en) * 2015-07-30 2019-05-02 Macrogenics, Inc. PD-1-Binding Molecules and Methods of Use Thereof
CN110087682A (zh) * 2016-12-19 2019-08-02 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
CN110392696A (zh) * 2017-01-06 2019-10-29 优特力克斯有限公司 抗-人4-1bb抗体及其应用
US20200165349A1 (en) * 2017-08-04 2020-05-28 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
CN110627906A (zh) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 抗pd-l1/4-1bb双特异性抗体及其用途
CN110669137A (zh) * 2019-10-24 2020-01-10 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途

Also Published As

Publication number Publication date
JP2024502371A (ja) 2024-01-18
WO2022149050A3 (en) 2023-04-20
KR102576861B1 (ko) 2023-09-11
KR102618718B1 (ko) 2023-12-29
US12331116B2 (en) 2025-06-17
WO2022149050A2 (en) 2022-07-14
EP4274852A4 (en) 2025-02-26
KR20220162808A (ko) 2022-12-08
US20220275083A1 (en) 2022-09-01
EP4274852A2 (en) 2023-11-15
KR20230031376A (ko) 2023-03-07

Similar Documents

Publication Publication Date Title
CN112672753B (zh) 融合构建体及其使用方法
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
RU2745451C1 (ru) Антитела к человеческому интерлейкину-2 и их применение
CN110545845A (zh) 抗cd33抗体药剂
TWI922434B (zh) 一種融合蛋白及其用途
KR20220082775A (ko) 항-pd-1 항체 및 이의 용도
JP2025098135A (ja) Ｐｄ－１ポリペプチド変異体
US20250270323A1 (en) Hhla2 binding agents with novel activity
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
KR102576861B1 (ko) 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
CN114716548A (zh) 抗-fgfr3抗体及其用途
KR20230034154A (ko) 신규 항 muc1항체 및 이의 용도
EP3882271A2 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
KR20260068059A (ko) 탈-N-아세틸화 폴리시알산 (dPSA) 결합제, 접합체, 및 그의 사용 방법
HK40103619A (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
KR20220082776A (ko) 항-tigit 항체 및 이의 용도
HK40096182A (en) Pharmaceutical composition and use thereof
HK40124330B (en) Anti-cd39 antibodies and use thereof
HK40113788A (en) Anti-cd39 antibodies and use thereof
CN118767127A (zh) 抗ctla4-抗pd-1双特异性抗体的医药用途
HK40105227A (en) Anti-pd-1 antibody and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103619

Country of ref document: HK